In ISOS we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery
of therapeutic compounds employing large ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor. This project is funded by the European Union’s EIC-Pathfinder Programme, under the Grant Agreement number 101130454
About ISOS
Vision
ISOS presents a visionary approach to in situ fabrication and auto-renewed delivery of therapeutic compounds.
ISOS aims to seamlessly integrate genetically engineered bacteria into a biomaterial-based bioreactor.
ISOS targets the wet form of age-related macular degeneration, proposing a genetically engineered bacteria bioreactor to replace frequent injections against vascular endothelial growth factor.
This initiative holds the promise of transforming prolonged treatments into personalised, efficient and minimally invasive healthcare experiences.
About us
Discover more about ISOS
ISOS is designed to treat chronic diseases requiring lengthy treatments.
The encapsulated GEB populations produce the therapeutic molecules «on demand», stimulated by the signals of the pathological environment within the patient, i.e., inflammation and/or reactive oxygen species. Bacteria populations interact among them to maintain a dynamic equilibrium of the GEB species and to guarantee the survival of the drug-producing GEB as long as the disease persists.
Discover more about ISOS here:
Our Latests post
Discover the latest news about ISOS
In-person Consortium Meeting In Leipzing
On March 31st-April 1st the ISOS Project EU Consortium Met in Leipzig, Germany.
VivaTech Paris
Ed Elafia from Alien attended the VivaTech Paris 22-25th May 2024 in Paris (France).
10th EU-Startups Summit
Miroslava from Alien attended the 10th EU-Startups Summit that took place in Malta on May 9-10.
Contact with us